RPG Life Sciences Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹4,968 Cr
- P/E
- 42.57
- ROE
- 19.31%
- PEG
- 2.49
- Price to sales
- 6.77
- Debt to equity
- 0.03
- 52W high / low
- ₹3,089 / ₹1,744
- Sales growth (5Y)
- 12.70%
- EBITDA margin
- 21.14%
- Net profit margin
- 15.50%
- Promoter holding
- 72.95%
- Sales (last year)
- ₹734 Cr
Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients[1]
Guidance scorecard · Q1 FY27 call
What RPG LifeScience.'s management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ4 FY26 call
10–20%- Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2% industry).
- Focus on volume-backed growth rather than relying on price increases, especially as 30% of products fall under DPCO (Drug Price Control Order).
- New products in pipeline expected to launch with higher gross margins, enabling better price growth than previous years.
- International formulation segment poised for growth from FY27 onwards after temporary inventory rationalization, with expansion into new markets like Africa.
- API business seen as a significant medium-term growth driver, with 144% Q4 bounce back and a strong pipeline of 13 new products; consistent 9-10% growth expected.
2 more points from RPG LifeScience.'s call on revenue
Create a free account to keep reading this call
MarginsQ4 FY26 call
FlatSee what RPG LifeScience. said on margins — free account, 30 seconds.
CapexQ4 FY26 call
Planned- RPG Life Sciences has invested over INR 140 crores in capex over the last 4-5 years, focusing on modernizing and expanding facilities to drive cost efficiencies and position for future growth.
- The company continues to invest in strengthening organizational capabilities and leadership pipeline via succession planning and capability-building initiatives.
- Strategic focus is on both organic and inorganic growth, with the company actively looking for prudent, value-accretive inorganic opportunities in formulations and API business through M&A.
2 more points from RPG LifeScience.'s call on capex
Create a free account to keep reading this call
FundraisingQ4 FY26 call
See what RPG LifeScience. said on fundraising — free account, 30 seconds.
Order bookQ4 FY26 call
Rising- Inventory rationalization in international formulations by some customers was described as a temporary blip, with stable order flow expected going forward.
- The company remains focused on expanding customer relationships, increasing market presence, and launching new products across markets.
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track RPG LifeScience..
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingRPG LifeScience. announcements
All announcements →- Acquisition / mergerNotableRPG Life Sciences completes acquisition of Actis Generics Private Limited
Financials of RPG LifeScience.
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
RPG LifeScience.
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 72.82% | 72.82% | 72.82% | 72.82% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% |
| FIIs + | 0.56% | 0.90% | 1.15% | 1.35% | 1.30% | 1.46% | 1.35% | 1.11% | 1.00% | 0.87% | 0.95% | 0.87% |
| DIIs + | 1.77% | 2.16% | 2.61% | 5.45% | 6.06% | 6.14% | 6.49% | 6.70% | 7.04% | 7.45% | 8.68% | 9.93% |
| Public + | 24.85% | 24.12% | 23.44% | 20.40% | 19.70% | 19.46% | 19.22% | 19.23% | 19.01% | 18.72% | 17.42% | 16.24% |
| No. of Shareholders | 21,866 | 22,137 | 22,232 | 23,481 | 24,891 | 24,867 | 25,832 | 26,657 | 25,905 | 25,282 | 23,886 | 24,330 |
Financials of RPG LifeScience.
Quarterly Results
Quarter-by-quarter operating performance
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 148 | 154 | 154 | 127 | 165 | 172 | 173 | 143 | 169 | 182 | 180 | 177 | 196 |
| Expenses + | 116 | 116 | 116 | 106 | 126 | 126 | 124 | 118 | 133 | 143 | 140 | 144 | 152 |
| Operating Profit | 32 | 37 | 38 | 21 | 39 | 46 | 49 | 25 | 35 | 39 | 40 | 33 | 44 |
| OPM % | 22% | 24% | 25% | 16% | 24% | 27% | 28% | 18% | 21% | 21% | 22% | 19% | 22% |
| Other Income + | 2 | 2 | 2 | 2 | 2 | -25 | 3 | 115 | 5 | 16 | -5 | 13 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Profit before tax | 30 | 35 | 36 | 18 | 36 | 15 | 47 | 135 | 35 | 49 | 29 | 40 | 41 |
| Tax % | 26% | 26% | 26% | 25% | 26% | 72% | 26% | 13% | 26% | 25% | 24% | 26% | 26% |
| Net Profit + | 22 | 26 | 26 | 13 | 27 | 4 | 35 | 117 | 26 | 37 | 22 | 30 | 31 |
| EPS in Rs | 13.36 | 15.64 | 16.00 | 8.01 | 16.18 | 2.54 | 21.12 | 70.95 | 15.90 | 22.28 | 13.38 | 18.08 | 18.48 |
Financials of RPG LifeScience.
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 242 | 279 | 294 | 344 | 330 | 376 | 389 | 440 | 513 | 582 | 653 | 708 | 734 |
| Expenses + | 228 | 256 | 274 | 306 | 296 | 315 | 318 | 353 | 408 | 453 | 493 | 560 | 579 |
| Operating Profit | 14 | 23 | 20 | 38 | 34 | 60 | 71 | 87 | 104 | 129 | 161 | 148 | 155 |
| OPM % | 6% | 8% | 7% | 11% | 10% | 16% | 18% | 20% | 20% | 22% | 25% | 21% | 21% |
| Other Income + | 1 | 1 | 18 | 1 | 1 | -5 | 1 | 3 | 4 | 7 | 95 | 29 | 28 |
| Interest | 3 | 2 | 4 | 5 | 5 | 3 | 2 | 1 | 1 | 1 | 2 | 2 | 1 |
| Depreciation | 11 | 10 | 11 | 14 | 15 | 16 | 16 | 16 | 16 | 17 | 21 | 21 | 22 |
| Profit before tax | 1 | 12 | 23 | 20 | 15 | 36 | 54 | 73 | 92 | 118 | 233 | 154 | 160 |
| Tax % | 0% | 0% | 10% | 34% | 28% | 20% | 25% | 30% | 26% | 26% | 21% | 25% | |
| Net Profit + | 1 | 12 | 21 | 13 | 11 | 29 | 40 | 51 | 68 | 88 | 183 | 115 | 119 |
| EPS in Rs | 0.60 | 7.03 | 12.70 | 8.13 | 6.54 | 17.54 | 24.19 | 31.13 | 40.90 | 53.00 | 110.79 | 69.64 | 72.22 |
| Dividend Payout % | 132% | 23% | 22% | 30% | 37% | 23% | 30% | 31% | 29% | 30% | 22% | 34% |
Financials of RPG LifeScience.
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 112 | 120 | 134 | 142 | 147 | 163 | 203 | 243 | 294 | 362 | 517 | 592 |
| Borrowings + | 33 | 23 | 45 | 54 | 36 | 12 | 2 | 1 | 0 | 0 | 0 | 20 |
| Other Liabilities + | 39 | 49 | 55 | 82 | 54 | 78 | 85 | 88 | 112 | 138 | 127 | 168 |
| Total Liabilities | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 | 793 |
| Fixed Assets + | 105 | 109 | 137 | 131 | 128 | 123 | 113 | 104 | 124 | 114 | 172 | 197 |
| CWIP | 1 | 2 | 2 | 9 | 17 | 10 | 12 | 31 | 25 | 96 | 16 | 23 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58 | 91 | 127 | 120 |
| Other Assets + | 92 | 94 | 108 | 152 | 106 | 134 | 178 | 210 | 211 | 212 | 343 | 454 |
| Total Assets | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 | 793 |
Financials of RPG LifeScience.
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -2 | 33 | 7 | 15 | 46 | 50 | 58 | 65 | 91 | 94 | 78 | 56 |
| Cash from Investing Activity + | -10 | -15 | -30 | -16 | -19 | -11 | -8 | -35 | -106 | -79 | -42 | 51 |
| Cash from Financing Activity + | 12 | -18 | 23 | 0 | -26 | -39 | -10 | -14 | -17 | -20 | -27 | -21 |
| Net Cash Flow | -0 | -0 | 1 | -1 | 0 | 0 | 40 | 17 | -32 | -5 | 9 | 87 |
| Free Cash Flow | -12 | 18 | -48 | -1 | 26 | 39 | 50 | 41 | 58 | 25 | 151 | -9 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 14% | 150% | 58% | 48% | 144% | 94% | 94% | 96% | 111% | 96% | 81% | 63% |
Financials of RPG LifeScience.
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 48 | 49 | 72 | 43 | 62 | 54 | 27 | 27 | 31 | 48 | 60 |
| Inventory Days | 149 | 156 | 163 | 171 | 136 | 133 | 162 | 214 | 203 | 200 | 159 | 179 |
| Days Payable | 109 | 135 | 102 | 165 | 83 | 127 | 132 | 117 | 138 | 140 | 135 | 141 |
| Cash Conversion Cycle | 101 | 70 | 110 | 78 | 96 | 68 | 84 | 124 | 91 | 90 | 72 | 99 |
| Working Capital Days | 27 | 26 | 20 | 22 | 20 | 41 | 52 | 47 | 33 | 25 | 45 | 64 |
| ROCE % | 2% | 9% | 10% | 13% | 10% | 23% | 27% | 31% | 33% | 35% | 33% | 26% |
Momentum score · price trend
78 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +23.0% | 75% |
| Last 6 months | +30.9% | 81% |
| Last 3 months | +8.1% | 77% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For RPG LifeScience.: 0.4 × 75 + 0.4 × 81 + 0.2 × 77 = 78.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What RPG LifeScience.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY